ESC symposium webcast
The ESC symposium "Routine platelet function monitoring in patients undergoing PCI" is available as webcast. ...read more
2011-12-02
Roche acquires Verum Diagnostica
to strengthen portfolio in coagulation diagnostics ...read more
2011-11-18
Platelet function testing recommended by latest ACCF/AHA/SCAI Guideline
for patients undergoing coronary interventions with stenting. ...read more
2011-09-19
Phenotyping with Multiplate outperforms genotyping
for the prediction of PCI patients at risk for stent thrombosis and MACE ...read more
This is the Multiplate® internet site for non-US residents.
Roche acquires Verum Diagnostica GmbH to strengthen portfolio in coagulation diagnostics. To view full press release please refer to www.cobas.com.
Introduced in 2005, Multiplate® is one of the most widely applied platelet aggregometers in Europe. Using simple whole blood analysis and intuitive software, Multiplate® is easy to implement in routine laboratory and near patient environments. Multiplate® is the method of choice for many European and international centers and is regarded by many experts as the analyser best suited for the clinical monitoring of antiplatelet therapy.
Multiplate® is
+ fast
10 minute test time
measures directly in whole blood
no need for centrifugation
+ standardized
ce marked instrument, reagents, test cells, wide range of dedicated reagents, widely applied instrument
+ cost effective
competitively priced instrument and analysis.
+ predictive
sensitive for aspirin, clopidogrel, IIb/IIIa antagonists, predictive for both transfusion requirements and thrombotic events*, positive experiences from a large number of clinical centers throughout Europe
*The largest study to date evaluating the clinical impact of clopidogrel resistance (n=1608) has shown that patients, stratified as inadequate responders according to Multiplate® analysis exhibited a 9.4 fold increased risk of stent thrombosis (Sibbing D et al. J Am Coll Cardiol 2009; 53(10):849-56). In a recent study Siller-Matula et al reported a superior predictivity for stent thrombosis for Multiplate® compared to the flow-cytometric VASP test (Multiple Electrode Aggregometry better predicts stent thrombosis than the VASP phosphorylation assay. J Thromb Haemost. 2009 Nov 23). The predictivity of Multiplate® analysis has also been demonstrated in neuroradiology (Mueller-Schunk S et al, AJNR 2008;29(4):786-9). Several studies have also shown that Multiplate® analysis is predictive for transfusion requirements in cardiac surgery (Rahe-Meyer N et al, Acta Anaesthesiol Scand. 2009 Feb;53(2):168-75; Rahe-Meyer N et al. Anesth Analg. 2008 Dec;107(6):1791-7; Mengistu AM et al, J Cardiothorac Vasc Anesth. 2008 Feb;22(1):40-6).
Further applications of Multiplate include the screening for platelet defects, the functional assessment of heparin induced thrombocytopenia (HIT), as well as pharmacological studies. Due to its small sample volume (0.3 ml of blood and 0.175 ml using a special mini test cell) Multiplate is well suited for pediatric applications and animal studies.